Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease.
Polymorphisms in the promoter region of the apolipoprotein E gene (APOE) affect the amount of amyloid peptide (Abeta) in the brains of patients with Alzheimer's disease. We measured Abeta load immunohistochemically in regions 8 and 9 of Brodman's area in 74 people with Alzheimer's disease. The amount of Abeta deposition was independent of APOE genotype in our cohort. These findings in patients with confirmed Alzheimer's disease are consistent with the hypothesis that variation in APOE expression directly affects Alzheimer's disease pathology.